Screening of Contralateral Breast in Patients with Breast Cancer: Role of MR Imaging and PET/CT Imaging

被引:0
作者
Weinstein, Susan [1 ]
Chawla, Madhavi [2 ]
Kumar, Rakesh [2 ]
机构
[1] Univ Penn, Med Ctr, Div Breast Imaging, Dept Radiol, Philadelphia, PA 19104 USA
[2] All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, India
关键词
Contralateral breast screening; Magentic resonance imaging; PET; PET-CT; Breast cancer;
D O I
10.1016/j.cpet.2009.09.009
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Breast cancer is one of the most common cancers in women. Contralateral breast carcinoma is the most common second malignancy in patients with breast carcinoma. Bilateral breast carcinomas exist in 2 forms: synchronous, in which both tumors occur at the same time, or metachronous, in which they occur at different times. When breast cancer is diagnosed, the contralateral breast should be carefully evaluated for a synchronous tumor. Screening for occult contralateral breast cancer is very important on initial cancer diagnosis. The detection and treatment of a synchronous tumor allows for informed surgical decision making, especially if tissue reconstruction is being considered. If chemotherapy is necessary, the patient would only need treatment once for bilateral synchronous cancers, not twice, as with metachronous cancers.
引用
收藏
页码:343 / 347
页数:5
相关论文
共 27 条
[1]   EVALUATION OF BREAST MASSES AND AXILLARY LYMPH-NODES WITH [F-18] 2-DEOXY-2-FLUORO-D-GLUCOSE PET [J].
ADLER, LP ;
CROWE, JP ;
ALKAISI, NK ;
SUNSHINE, JL .
RADIOLOGY, 1993, 187 (03) :743-750
[2]   Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: Comparison with CT and PET [J].
Antoch, G ;
Saoudi, N ;
Kuehl, H ;
Dahmen, G ;
Mueller, SP ;
Beyer, T ;
Bockisch, A ;
Debatin, JF ;
Freudenberg, LS .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) :4357-4368
[3]   Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology [J].
Antoch, G ;
Vogt, FM ;
Freudenberg, LS ;
Nazaradeh, F ;
Goehde, SC ;
Barkhausen, J ;
Dahmen, G ;
Bockisch, A ;
Debatin, JF ;
Ruehm, SG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (24) :3199-3206
[4]   Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)fluoro-2-deoxy-D-glucose [J].
Avril, N ;
Dose, J ;
Janicke, F ;
Ziegler, S ;
Romer, W ;
Weber, W ;
Herz, M ;
Nathrath, W ;
Graeff, H ;
Schwaiger, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) :1204-1209
[5]  
Bassa P, 1996, J NUCL MED, V37, P931
[6]  
BURNS PE, 1984, CAN MED ASSOC J, V130, P881
[7]   Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? [J].
Coradini, D ;
Oriana, S ;
Mariani, L ;
Miceli, R ;
Bresciani, G ;
Marubini, E ;
Di Fronzo, G .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (06) :825-830
[8]   BILATERAL BREAST-CANCER - ONE DISEASE OR 2 [J].
DAWSON, PJ ;
MALONEY, T ;
GIMOTTY, P ;
JUNEAU, P ;
OWNBY, H ;
WOLMAN, SR .
BREAST CANCER RESEARCH AND TREATMENT, 1991, 19 (03) :233-244
[9]  
EGAN RL, 1976, CANCER, V38, P931, DOI 10.1002/1097-0142(197608)38:2<931::AID-CNCR2820380242>3.0.CO
[10]  
2-O